CT Volume Measurement of Hepatocellular Carcinoma

NCT07183566 | Not Yet Recruiting

• 1 other identifier: Ct volume measaurement of HCC
• Study Type: observational
• Target: 66
• Locations: 0 countries
• Sites: N/A

Brief Summary

The aim of this study is to evaluate the role of CT volumetric measurement in assessing treatment response of hepatocellular carcinoma (HCC) following trans arterial chemoembolization (TACE) or microwave ablation (MWA)

Conditions

Hepatocellular Carcinoma (HCC); CT

Outcome Measures

Primary Outcomes (1)

• Ct volume measurent of hepatocellular carcinoma after Transarterial chemoembolization or microwave ablation

  At enrollment, all patients will undergo a comprehensive clinical assessment, including full medical history with emphasis on risk factors for hepatocellular carcinoma triphasic CT scan of the liver, which will serve as the reference for tumor volume (by cm3 or cc), number, and distribution prior to TACE or MWA.

  Baseline

Interventions

Ct DEVICE

Ct volume measurement of HCC after TACE or MWA

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All patients admitted to Assiut University Hospital, Egypt during the period of the study and fulfil the inclusion criteria

You may qualify if:

• Adult patients (≥18 years) with a confirmed diagnosis of HCC based on AASLD or EASL criteria.
• Patients deemed unresectable by the multidisciplinary tumor board.
• Patients scheduled for TACE as the primary locoregional therapy.
• Preserved liver function (Child-Pugh class A or B).
• Adequate renal function to permit contrast-enhanced CT.

You may not qualify if:

• Patients with extrahepatic metastases or portal vein thrombosis.
• Patients with contraindications to iodinated contrast or TACE.
• Patients with severe comorbid illness that precludes participation.
• Patients refuse to provide informed consent.

Sponsors & Collaborators

• Assiut University: lead

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Liver Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Liver Diseases

Central Study Contacts

Ahmes Saber Hamed, Master

CONTACT

+2001019545804; Ahmed.17289721@med.aun.edu.eg

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant lecturer

Study Record Dates

• First Submitted: September 12, 2025
• First Posted: September 19, 2025
• Study Start: October 1, 2025
• Primary Completion (Estimated): October 1, 2027
• Study Completion (Estimated): November 1, 2027
• Last Updated: September 19, 2025

Record last verified: 2025-09